分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

Fibroblast growth factor 2 (FGF2) ameliorates the coagulation abnormalities in sepsis

Yuanyuan Sun, Fanrong Ye, Ding Li, Hongjing Yang, Tingting Xu, Xincun Zhong, Yilun Lu, Hongmin Zhou, Jingye Pan

Journal:TOXICOLOGY AND APPLIED PHARMACOLOGY

IF:3.8

DOI:10.1016/j.taap.2023.116364

PMID:36621722

Published:2023-01-06

research field:神经科学干细胞生物学结构生物学

Abstract

Background Sepsis is defined as a life-threatening organ dysfunction caused by dysregulation of the host response to infection. There is still a lack of specific treatment for sepsis. Here, we report that Fibroblast growth factor-2 (FGF2) can reduce the mortality of sepsis by ameliorating the coagulation abnormalities. Methods FGF2 was intraperitoneally injected into septic mice induced by lipopolysaccharide (LPS) and then assessed for coagulation response, organ damage and survival. RAW264.7 cells with or without FGF2 pretreating were exposed to LPS, and then changes in coagulation related factors expression and signaling were tested. Results The findings showed that intraperitoneal injection of FGF2 inhibited coagulation activity, reduced lung and liver damage, and increased survival in septic mice. In RAW264.7 cells, LPS upregulated the expression of tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1); however, pretreatment with FGF2 prevented this upregulation, while FGF2 knockdown exacerbated TF upregulation. Moreover, FGF2 suppressing the AKT/mTOR/S6K1 signaling pathway in septic mice and RAW264.7 cells stimulated by LPS. Conclusions This study revealed a therapeutic role of FGF2 in ameliorating the coagulation abnormalities during sepsis.

本文使用的Yeasen产品

购物车
客服
转染试用